Stratosvir

Executive Summary

Stratosvir is a London-based biotech company founded in 2020, dedicated to developing viral immunotherapies for solid tumors and metastases. The company's platform leverages oncolytic viruses to selectively infect and destroy cancer cells while stimulating the immune system, offering a potential non-toxic alternative to conventional treatments. Stratosvir aims to improve both quality of life and survival for cancer patients by targeting hard-to-treat solid tumors. Despite being in early stages with no disclosed funding or pipeline details, the company's focus on viral immunotherapy aligns with a growing field that has seen clinical successes. Stratosvir's approach is differentiated by its emphasis on safety and efficacy, addressing the unmet need for treatments that are both effective and less toxic than chemotherapy. As a private, pre-clinical stage company, Stratosvir's near-term value hinges on advancing its lead candidates toward clinical testing. The company's progress will depend on securing financing, generating preclinical proof-of-concept data, and navigating regulatory pathways in the UK and other markets. While the viral immunotherapy space is competitive, Stratosvir's unique positioning and patient-centric mission could attract partnerships or investment. However, given the lack of public milestones, the conviction score is moderate, reflecting the high risk inherent in early-stage biotech. The company's ability to execute on its vision will be critical in the coming years as it seeks to move from bench to bedside.

Upcoming Catalysts (preview)

• Q2 2026Preclinical Proof-of-Concept Data Release60% success
• Q4 2026Series A Financing Round50% success
• Q2 2027IND Filing for Lead Candidate30% success